Home | Welcome to Contract Pharma   
Last Updated Thursday, August 28 2014
Print RSS Feed

Oxford Biomedical Awarded NIH Grant



By Kristin Brooks



Published December 10, 2013
Related Searches: Testing Phase II Development
Oxford Biomedical Research, Inc. has been awarded a Phase II Small Business Innovation Research Grant by the National Institute of Environmental Health Sciences. The grant, valued at $1.2 million, is for the development of a panel of tests designed to use GST proteins as more sensitive and specific biomarkers to detect toxicity and differentiate potential toxic effects to multiple organs.
 
GST proteins, found in many tissues and organs, play an important role in the elimination of drugs and environmental compounds that humans are exposed to and are considered extremely sensitive biomarkers for toxicity.
 
Researchers at Oxford Biomedical Research have already assembled tests for a number of GST proteins. The NIH-funded research includes development of a device that can rapidly and inexpensively measure multiple GSTs. The utility of GSTs for organ-specific toxicity testing will be validated by comparison to conventional toxicity tests used during drug development and in the clinic.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On